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ABSTRACT
SAVANNAH FAIRLEY: Synthesis of (2R,6R)- Hydroxynorketamine for Evaluation
of Antidepressant Effects
(Under the direction of Dr. John Rimoldi)
Major Depressive Disorder, colloquially known as depression, is a devastating
mental illness that affects a large portion of today’s population. Following a drug
side-effect that caused depression, the monoamine theory of depression was created,
stating that depressive symptoms were caused by a decrease in concentrations of vital
monoamine neurotransmitters at the synaptic cleft. Pharmaceutical remedies to
combat depression were first introduced in the 1950s and to this date, most available
drugs follow the monoamine theory. These drugs have a large loading dose lag time,
numerous negative side effects, and still many patients do not experience relief from
symptoms. In 2000, the Stress-neurogenic theory was proposed, suggesting
depressive symptoms decreased neurogenesis and dendritic retraction, induced by
excess cortisol from chronic stress. This new theory opened the door for further
studies to be conducted on possible pharmacotherapies for MDD. Ketamine had
shown some antidepressant effects, but was not a sufficient option due to the
dissociative effects and history of abuse. Further studies were done to indicate that
ketamine’s antidepressant effects were caused by the metabolite (2R,6R)hydroxynorketamine and that the mechanism of action seems to be NMDA receptor
independent. The goal of this thesis was to construct an efficient complete synthesis
pathway of (2R,6R)- hydroxynorketamine from commercially available chemicals.
This was done by evaluating chemically and structurally similar reactions that had
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been previously published to piece together a new synthesis of (2R,6R)-HNK. The
product of this research will be sent to a partnering lab for further studies to be
completed on the NMDA-independent and possibly AMPA receptor-dependent
mechanism by which ketamine exhibits such promising antidepressant effects.
Further understanding of this mechanism brings us one step closer to better future
pharmacotherapies for MDD.
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Introduction

Morbidity of Major Depressive Disorder
Major Depressive Disorder (MDD), more commonly known as depression, is a
mental illness that is both chronic and debilitating, with a very high morbidity.1 It is
related to the natural emotion of sadness but does not remit once the external cause
dissipates.2 According to the 5th edition of the Diagnostic and Statistical Manual of
Mental Disorders, MDD is characterized by an individual exhibiting at least five of the
outlined depressive symptoms every day for a minimum of two weeks. These five
symptoms may include: changes in appetite or weight, slowing of speech and action,
disturbance of sleep schedule, strong feeling of worthlessness, lack of concentration, and
suicidal ideation or actions.1,2 MDD has a life time prevalence of 14.4%, making it the
most common mood disorder and the second most common mental illness in the United
States, second to anxiety.1 MDD has major socioeconomic consequences. Due to the
combination of high morbidity rates and debilitating symptoms, MDD places a huge
burden on the economy, contributing to $83.1 billion in healthcare expenses in the United
States (Year 2000 statistics).1 On average, workers that suffer from severe depressive
symptoms missed 13.7 more hours and cost their employers almost twice the healthcare
expenses per year compared to other workers.1
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History of MDD Treatments and Theories
There are several FDA approved therapies indicated for the treatment of MDD;
however, they have several key disadvantages that limit their effectiveness. In addition to
unwanted side effects, the pharmaceutical drugs designed to treat MDD have a delayed
onset of about 4-12 weeks before any measurable remission of symptoms are noticed.1
Even after this time period, some patients never experience therapeutic relief, despite
taking escalating doses. Those that fit into this category are considered to have treatment
resistant depression and they account for 34-46% of all MDD diagnosed patients.1
All of the FDA approved drugs indicated for the treatment of MDD are based on
the monoamine theory of depression, which claims that MDD patients have low
concentrations of serotonin, norepinephrine, and dopamine. Regardless of the therapeutic
class, all aim to produce an increase in the concentration of these monoamine
neurotransmitters at synaptic clefts. Evidence for the monoamine theory for depression
was based on the drug reserpine, used in the 1950s to treat hypertensive vascular disease.
Patients taking reserpine appeared to develop depression that remissed once the drug
therapy was terminated. Studies confirmed the findings that reserpine inhibited a
vesicular monoamine transporter and therefore lowered the concentrations of
monoamines in the brain.1 Another proof for the monoamine theory came from studies
using monoamine oxidase inhibitors (MAOIs). MAOIs target and inhibit the enzyme
monoamine oxidase, an enzyme responsible for the metabolism and clearance of
neurotransmitter amines, resulting in the increase in concentration of these
neurotransmitters. New therapeutics began to emerge with incremental advances in their
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pharmacological mechanisms of action, but with the same end result: they were designed
to increase concentrations of monoamine neurotransmitters at the neuronal synapses in
order to alleviate depressive symptoms.1
The next therapeutic class of drugs discovered after the MAOIs was the tricyclic
inhibitors of norepinephrine and serotonin. Drugs in this class inhibit presynaptic
norepinephrine and serotonin reuptake transporters as well as block postsynaptic
adrenergic alpha receptors, postsynaptic muscarinic receptors, and postsynaptic histamine
receptors.1 The inhibition of these reuptake transporters for both norepinephrine and
serotonin are cited to be the reason for the remission of symptoms, keeping in line with
the monoamine theory of depression.
Major advances in treating depression was realized with the discovery of the
selective serotonin reuptake inhibitors (SSRIs), which prevent the reuptake of serotonin
resulting in clinically relevant increases in concentrations in the synaptic cleft and a
higher concentration available to stimulate serotonin receptors at post-synaptic receptors.
Logically, serotonin-norepinephrine inhibitors (SNRIs) were developed, therapeutics able
to target both serotonin and norepinephrine reuptake receptors, but are more selective
than the tricyclic drugs.

Figure I. Summarized selective serotonin reuptake inhibitor mechanism of action.6
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These are just a few of the current MDD therapeutic classes that are FDA
approved Despite the variety in drug design and pharmacological mechanisms of actions,
all of the current drugs for MDD require a loading dose lag time before they are effective.
In addition, there are many treatment resistant MDD patients, which presents a need for
further research.

Figure II. Summary of Major Classes of Antidepressant Drugs.7

The Stress-Neurogenic Theory
Due to the large number of patients suffering from treatment resistant depression,
there is support that depletion of monoamines may be a side effect of a much larger
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neurobiological system in play.1 The shortcomings of current MDD treatments led
researchers to develop a new theory: the stress-neurogenic theory of depression. This
theory states that unpredicted or chronic stress causes a larger amount of stress hormones
to be produced, which in turn induce neuronal damage in areas of the brain, such as the
amygdala and the hippocampus. Stress causes the release of corticotrophin-releasing
hormone (CRH) from the hypothalamus that induces the release of corticotrophin from
the pituitary gland.1 Corticotrophin then activates the adrenal gland to release cortisol,
which in excess causes decreased neurogenesis and dendritic retraction, leaving the
neurons vulnerable to neurotoxicity and other metabolic changes.3 With this proposed
theory, research efforts have been redirected to finding novel treatment pathways.

History of Ketamine and its Use as an Antidepressant
The FDA approved ketamine in 1970 as a short-term, noncompetitive NMDA
receptor antagonist anesthetic in humans and animals, however it did not become widely
used until the Vietnam War. Due to its light and controllable dissociative effects,
ketamine’s role in pediatric and veterinary medicine grew rapidly, as did its popularity as
a recreational street drug. Recently, ketamine has been associated with antidepressant
effects. The administration of sub-anesthetic doses of ketamine to MDD patients has
shown strong and persistent efficacy, even within the first hour of the first dose.4
Although these findings bring great excitement to the field and to treatment resistant
patients, this drug has limitations due to its hallucinogenic and dissociative effects as well
as its abuse liability.4 For this reason, research efforts have focused on the identification
of ketamine’s direct antidepressant mechanism.
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In vivo pharmacology studies have demonstrated that the N-demethylated
metabolite norketamine exhibited approximately 50% of the anesthetic effects of
ketamine, while hydroxynorketamine (HNK) had no anesthetic effects at all.5 This led
researchers to hypothesize that norketamine was the active agent of ketamine and that its
clinical effects came from N-methyl-D-aspartate receptor (NMDAR) inhibition.4 These
studies led to the conclusion that hydroxynorketamine was therefore inactive.5

H 3C

O

O

NH

Cl

Cl

Ketamine

O

NH2

NH2

OH

Cl

Norketamine

(2R,6R)-Hydroxy-norketamine (HNK)

Figure III. Structure of Ketamine and two of its metabolites

More recent studies have investigated the concurrence of the antidepressant
effects and the inhibition at the NMDA receptors, and have proved that other NDMA
antagonists do not produce similar antidepressant effects.4 This data indicates that
ketamine’s antidepressant effects are likely due to an NMDAR inhibition- independent
mechanism. Additional studies were performed to specifically test hydroxylnorketamine’s antidepressant effects. Ketamine was altered so that its metabolites,
(2S,6S; 2R,6R)-hydroxynorketaine (HNK) would not form, however, the pharmacological
effects of the molecule were not affected. Studies showed that without (2S,6S or 2R,6R)HNK, antidepressant effects were not observed.4 It was confirmed that the (2R,6R)-HNK
enantiomer exhibited the most efficacy in antidepressant trials, which also negates the
NMDAR hypothesis since the S-HNK enantiomer is a more potent NMDAR inhibitor.4
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During trials, a single dose of (2R,6R)-HNK exhibited antidepressant effects similar to
those of ketamine; fast and persistent remission of symptoms.4
To further assess the mechanism of action of (2R,6R)-HNK, researchers used
tagged molecules bound at NMDA receptors to measure the metabolites antagonistic
effect. In the vitro studies, (2R,6R)-HNK did not displace the tagged molecules,
therefore the antidepressant effects of (2R,6R)-HNK are not associated with the NMDA
receptors.4 However, the metabolite did show an increase in α- amino-3-hydroxy-5methyl-4-isoxazolepropionic acid (AMPA) receptor mediated excitatory post-synaptic
potentials as well as an increase in the frequency and amplitude of AMPAR-mediated
excitatory postsynaptic currents.4 Studies confirmed the role of AMPA receptor
activation on antidepressant effects. Mice were pretreated with an AMPAR antagonist
prior to (2R,6R)-HNK injections, resulting in no noticeable antidepressant effects. This
indicated that activation of the AMPA receptors is required for (2R,6R)-HNK
antidepressant mechanism of action.4
Ketamine’s use as an antidepressant drug is limited due to the abuse liability and
the sensory, motor, and dissociative effects it causes. Studies prove that (2R,6R)-HNK
did not produce any sizable changes in motor and sensory process, even at high doses.4
Due to the lack of side effects and the NMDAR- independent mechanism of action;
(2R,6R)-HNK is a favorable molecule for the development of new, fast-acting
antidepressant drug treatments. The goal of this study was to develop a novel and
efficient complete synthesis of (2R,6R)-hydroxynorketamine to be used for in vivo
physiological studies.
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Results and Discussion
As a result of several milestone publications, it is now well-established that
the ketamine metabolite, (2R,6R)-hydroxynorketamine is a major contributor to
ketamine’s antidepressant effects. The specific aim of the thesis research outlined was
to design and execute a simple and cost-effective synthesis of (2R,6R)hydroxynorketamine (HNK). This compound will be tested in the laboratory of Dr.
Kenneth Sufka at the University of Mississippi using an innovative and unique in
vivo antidepressant screening model. This laboratory has developed and continues to
validate an avian social-separation stress procedure that simulates several
characteristics of treatment-resistant depression (TRD).13 Indeed, it is the only assay
that meets the FDA definition of TRD, which is the failure to respond to two classes
of FDA-approved antidepressants.14,15 If this model successfully screens HNK, this
may very well open the door to the development and screening of a broad library of
compounds related to HNK that may prove highly efficacious in TRD populations.
The design of synthetic pathways for this project began in Spring 2017; at this
time there were no synthetic reports published for (2R,6R)-hydroxynorketamine.
Since then, two total synthesis have been reported. Researchers at the Experimental
Therapeutics and Pathophysiology Branch, National Institute of Mental Health, NIH
reported the synthesis of (2R,6R)-hydroxynorketamine from (R)-ketamine (prepared
in 6 steps from cyclohexanone) using a Rubottom oxidation as the key step in the
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synthesis, providing a 72% yield and an excellent diastereomeric ratio to
install the α-keto-alcohol with the desired stereochemistry (Figure 4). 8

	
  

9	
  

Figure IV. Morris Synthesis, NIDA-NIH, 2017.8

A second synthesis of (2R,6R)-hydroxynorketamine was reported by Corey,
who utilized a mechanistically-guided catalyst selection (manganese) for the initial
olefin epoxidation step, and a novel O → N displacement with retention of
configuration through the use of Al- or Ti-based azides to promote epoxide activation
and internal cis delivery of azide (Figure 5). Although novel and elegant, the
synthesis is expensive due principally to the use of a chiral Mn catalyst and noncommercially available reagents.9
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Figure V. Corey Synthesis, Harvard, 2017 9

One theme emerges from the analysis of the reported syntheses: they both
invoke the synthesis of (R)-norketamine (or its protected version) followed by a latestage oxidation. Although these two papers described the successful synthesis of
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(2R,6R)-HNK, the goal of this thesis research was to design a new and
efficient synthesis, cost-effective and scalable. Our synthesis began with easily
accessible and commercially available starting materials, with the initial aim of
synthesizing gram scale racemic norketamine. The racemic material would then be
subject to diastereomeric salt formation for enantiomer resolution. Figure VI
illustrates the synthetic pathways employed.

Cl
Br

O

OH

O

b
a

Cl

1

Br

d

Cl

2

O
N3

e
Cl

c

O

H 2N

4

O

f
Cl

Cl

5

Cl

3

7

6

Figure VI: Synthesis of (rac)-Norketamine (7a). Experimental Conditions: a.) Mg,
THF, chlorobromobenzene, 1, (40%). b.) PTSA, toluene, reflux (92%); c.) NaHCO3
(15mL) NaHCO3, m-CPBA, (80%); d.) HBr (aq.), PCC, CHCl3 (39%). e.) DMSO,
NaN3 (82%). f.) PPh3, water, reflux.
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The synthesis of racemic norketamine (7) was initially reported by Sulake et
al. We adopted this methodology, apart from the use of deuterium labeled reagents
and made some improvements to the reported methods. Commercially available
bromo-chlorobenzene was converted to a Grignard reagent and reacted with
cyclohexanone (1) to yield the tertiary alcohol (2), which was subject to a dehydration
step affording olefin (3) in good yields. The low yielding Grignard reaction may be a
consequence of moisture present during the reaction. This step was not optimized.
The stage was set for an epoxidation reaction of 3 with m-CPBA; initial experiment
confirmed the findings that the epoxide generated was relatively unstable. A change
in the Rf value was noticed after the compound had been stored for a week at 0°C.
Therefore, the epoxidation was performed using a biphasic solution of
dichloromethane and 5% sodium bicarbonate to eliminate the potential for
rearrangement products, resulting in epoxide 4.8 The epoxide ring was then subjected
to regioselective epoxide ring-opening reaction with HBr followed by a PCCmediated oxidation to yield the targeted brominated ketone (5) in a one-pot reaction.
Compound 5 was then treated with sodium azide to afford product 6. A Staudinger
reaction was employed for the reduction of azide (6) to generate (rac)-norketamine 7.
The mechanism of this reaction involves the reaction of triphenyphosphine with the
terminal nitrogen of the azide, followed by a facile rearrangement, leading to the
intermediate iminophosphorane. Water attack on this intermediate leads to a
hydrolytic reaction generating amine and triphenylphosphine oxide as the by-product
(which is not easily separated from the product).
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Figure VII: Proposed Staudinger Reaction Mechanism. 10

A quantity of (rac)-norketamine (7) has been successfully synthesized, and
prior to enantiomeric resolution using a chiral salt, initial experiments were conducted
to explore a simple and cost effective late stage oxidation reaction. Reaction of 7
with methychloroformate afforded carbamate 8. Reactions are in progress to explore
the scope and utility of a new and simple oxidation reaction that has been recently
reported, namely the DMSO-Iodine promoted direct oxidation of carbonyl
derivatives. The simple and readily available iodine or NBS is used as catalyst, and
DMSO acts as the oxidant, oxygen source, and solvent.11 The interpretation of the
mechanism is that the oxidation should proceed from the less hindered face of the
cyclohexone ring, and facial selectivity should be improved by the directing effects of
the amine carbamate group. If this reaction proves successful, the remaining steps are
to conduct a deprotection reaction of the carbamate (KOH hydrolysis), and resolution
of the major cis-disasteromer.
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c, d

2R,6R HNK

Materials and Methods
General Methods
All reactions were completed using commercially available solvents and
reagents. Every reaction was done under standard anhydrous conditions, unless
otherwise stated. Standard anhydrous conditions meaning that oven-dried glassware
was purged with argon in order to remove all moisture and anhydrous “dry” solvents
were used. All reactions were monitored with thin layer chromatography (TLC) to
check amount of starting material leftover and for product formation.
Phosphomolybdic acid was used to stain all TLC plates, as it had the best results for
these compounds. Low-resolution mass spectroscopy was obtained at each step to
confirm that the product molecular weight was present. For all Nuclear Magnetic
Resonance (NMR) data, a Bruker 400 MHz Avance NMR spectrometer was used,
and all raw data was processed with MestReNova software.

(2) 1-(2-chlorophenyl)cyclohexan-1-ol
A Grignard reagent was created by adding a solution of obromochlorobenzene (2.2 mL) in dry THF (22 mL) drop wise to a mixture of Mg (0.5
g) and I2 (cat.) in anhydrous THF (8 mL) at 10-15 °C over 0.5 h. A solution of
cyclohexanone (2.29 mL) in dry THF (15 mL) was added to the Grignard reagent at
0°C and stirred for 1 h. The temperature was then slowly increased to 20-25°C and
the reaction continued to stir for 15 h. The mixture was quenched with sat. NH4Cl,
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added dropwise. The mixture was then extracted with an equal amount of EtOAc and
the organic layer was washed with brine, dried over Na2SO4 , and concentrated under
reduced pressure to give a yellow oil. The product was purified by silica gel column
chromatography (hexane/EtOAc, 10:1). This reaction yielded 1.59 g (40%) of 2. (1H
NMR (400 MHz, Chloroform-D) δ 7.72 – 7.45 (m, 1H), 7.40 – 6.91 (m, 3H), 2.49 (d,
J = 22.7 Hz, 1H), 2.27 – 2.02 (m, 2H), 2.01 – 1.42 (m,7H), 1.41– 1.05 (m, 1H),	
  13C
NMR (101 MHz, CDCl3) δ 144.96, 131.67, 128.15, 127.25, 127.01, 77.35, 77.04,
76.72, 73.91, 35.63, 25.34, 21.94.

(3) 1-(2-chlorophenyl)cyclohexene
Compound 2 (1.59 g) was dissolved in toluene (32 mL) and dehydrated by
refluxing with PTSA (75 mg) and using azeotropic distillation by way of a DeanStark condenser. The mixture refluxed for 3 hours at 160°C and then left to stir at
room temperature for 12h. The reaction mixture was washed with saturated NaHCO3
and water. The organic layer was dried over Na2SO4 and then concentrated under
pressure to give 1.34 g (92%) as a colorless oil. (1H NMR (400 MHz, Chloroform-D)
δ 7.43 – 7.24 (m,2H), 7.26 – 7.14 (m, 4H), 5.70 (s,1H), 5.65 (s, 1H), 2.33 (td, J = 5.9,
2.8 Hz, 3H), 2.22 (tt, J = 7.1, 3.6 Hz, 3H), 2.18 (s, 3H), 1.85 – 1.69 (m, 7H), 13C
NMR (101 MHz, CDCl3) δ 143.48, 137.67,132.45, 130.17, 129.47, 127.71, 127.25,
126.55, 100.00, 77.35, 77.03, 76.71, 29.15, 25.40, 22.88, 22.0
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(4) 1-(2-chlorophenyl)-7-oxabicyclo[4.1.0]heptane
A solution of 5% NaHCO3 (15 mL) was added to m-CPBA (1.48 g, 8.6 mmol)
in DCM (15 mL) and stirred and 0°C. Compound 3 was dissolved in DCM (3 mL)
and added dropwise to this solution, which was then stirred for 15 h at room
temperature. The reaction mixture was separated using H2O, dried over Na2SO4. The
compound was purified with silica gel chromatography (hexane/EtOAc, 10:1) to yield
1.32 g (80%) colorless oil. (1H NMR (400 MHz, Chloroform-D) δ 7.46 (dd, J =7.2,
2.0 Hz, 1H), 7.43 – 7.31 (m, 1H), 7.30 – 7.17 (m, 2H), 2.08 (ddq, J = 30.1, 14.7, 8.7,
7.3 Hz, 3H), 1.68 – 1.39 (m, 3H), 13C NMR (101 MHz, CDCl3) δ 141.23, 132.10,
128.96, 128.53, 127.99, 126.78, 100.00, 77.35, 77.04, 76.72, 60.58, 60.02, 29.43,
24.78, 20.31, 18.80).

(5) 2-bromo-2-(2-chlorophenyl)cyclohexanone
Compound 4 (1.32 g, 6.35 mmol) was dissolved in chloroform (30 mL) and
stirred with 48% aq. hydrobromic acid (17 mL) at 0°C for 0.5 h. The aqueous layer
was separated and then extracted three times with chloroform (3x 10 mL). The
combined organic layer was then washed with equal amounts of sat. aq. NaHCO3.
The solvent was evaporated off and the residue was redissolved in DCM (20 mL).
Pyridinium chlorochromate was added to this solution and stirred at RT for 13h. The
reaction mixture was filtered through celite and then washed with HCl and water.
Organic layer was washed with water and brine and then dried over Na2SO4. The
product was concentrated under pressure and then purified using silica gel
chromatography (hexane/EtOAc, 10:1) to yield 700 mg (39%) of a colorless oil. (1H
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NMR (400 MHz, Chloroform-D) δ 7.99 (d, J =7.4 Hz, 1H), 7.37 (ddq, J = 24.3, 16.3,
8.8, 8.1 Hz, 4H), 3.09 (dd, J = 15.3, 8.4 Hz, 1H), 3.00 – 2.90 (m,1H), 2.65 (d, J = 15.4
Hz, 1H), 2.41 (d, J = 15.1 Hz, 1H), 1.95 – 1.89 (m, 1H), 13C NMR (101 MHz,
CDCl3) δ 201.43, 170.66, 137.86, 131.89, 131.34, 130.96, 129.71, 127.37, 77.35,
77.03, 76.71, 73.55, 43.09, 37.38, 25.56, 22.63.

(6) 2-azido-2-(2-chlorophenyl) cyclohexanone
DMSO (3.67mL) was used to create a solution of compound 5 (700mg). NaN3
(468mg) was added to the DMSO solution and stirred at 25°C for 5 h. The reaction
mixture was combined with water (10mL) and extracted with ethyl acetate (10mL x
3). The organic layer was then washed with water and then dried over Na2SO4. The
compound was purified using silica gel chromatography (hexane/EtOAc, 10:1) and
gave 500mg (82%) as a colorless oil. (1H NMR (400 MHz, Chloroform-d) δ 7.47
7.26 (m,1H), 2.75 – 2.47 (m, 1H), 2.07 – 1.95 (m, 1H), 1.86 (ddddd, J = 27.6, 18.9,
14.0, 8.3, 4.3 Hz, 1H), 13C NMR (101 MHz, CDCl3) δ 203.26, 137.13, 132.46,
131.35, 129.67, 127.95, 127.35, 77.34, 77.03, 76.71, 74.05, 38.86, 37.58, 25.41,
21.31).

(7) 2-amino-2-(2-chlorophenyl) cyclohexanone
Triphenylphosphine (600mg) was added to a solution of THF (10mL) and
compound 6 (500mg). This mixture refluxed for 12 h at 65°C, water (0.15mL) was
added and the mixture continued to reflux for 3 h. The solvent was removed under
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pressure and the compound was diluted with DCM (7mL) and 1M HCl (7mL). Sat.
NaHCO3 was used to basify the aqueous layer, which was then extracted with DCM
(3 x 10mL). The organic layer was washed with water and dried over Na2SO4. The
compound was concentrated under pressure to yield a colorless oil. (1H NMR (400
MHz, Chloroform-d) δ 7.80 – 7.73 (m, 3H), 7.72 – 7.62 (m, 25H), 7.59 – 7.51 (m,
16H), 7.51– 7.40 (m, 28H), 7.40 – 7.35 (m, 4H), 7.35 – 7.27 (m,4H), 3.32 (s, 1H),
2.62 – 2.57 (m, 1H), 2.02 (s, 1H), 1.84 – 1.74 (m, 4H), 1.26 (s, 4H), 13C NMR (101
MHz, CDCl3) δ 170.66, 132.96, 132.14, 132.04, 131.99, 131.96, 131.92, 131.20,
129.95, 128.58, 128.55, 128.46, 127.51, 77.40, 77.08, 76.76, 38.92, 29.70, 22.00).
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